Synairgen Overview
- Year Founded
-
2003

- Status
-
Public
- Employees
-
33

- Stock Symbol
-
OMY

Synairgen General Information
Description
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.
Contact Information
Website
www.synairgen.comCorporate Office
- Mailpoint 810
- Southampton General Hospital, Tremona Road
- Southampton SO16 6YD
- England, United Kingdom
Corporate Office
- Mailpoint 810
- Southampton General Hospital, Tremona Road
- Southampton SO16 6YD
- England, United Kingdom
Synairgen Stock Performance
As of 08-Apr-2025, Synairgen’s current market cap is $8.42M with 1.1B shares.
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$8.42M | 1.1B | 7.16K | -$0.03 |
Synairgen Financials Summary
As of 30-Jun-2024, Synairgen has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | (4,613) | (3,135) | 10,913 | 501,319 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (10,874) | (12,689) | (24,893) | (79,306) |
Net Income | (8,716) | (10,451) | (21,747) | (66,918) |
Total Assets | 13,457 | 18,116 | 28,475 | 60,245 |
Total Debt | 0 | 0 | 0 | 0 |
Synairgen Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Synairgen Comparisons
Industry
Financing
Details
Synairgen Competitors (31)
One of Synairgen’s 31 competitors is Verona Pharma, a Private Debt Financed company based in London, United Kingdom.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Verona Pharma | Private Debt Financed | London, United Kingdom | ||||
Ventus Therapeutics | Venture Capital-Backed | Waltham, MA | ||||
Pulmatrix | Formerly VC-backed | Framingham, MA | ||||
Theravance Biopharma | Corporation | San Francisco, CA | ||||
Savara | Formerly VC-backed | Langhorne, PA |
Synairgen Patents
Synairgen Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-202106014-D0 | Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients | Inactive | 27-Apr-2021 | ||
US-20230241177-A1 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid | Pending | 08-Sep-2020 | ||
GB-202014114-D0 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid | Inactive | 08-Sep-2020 | ||
EP-4210728-A1 | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid | Pending | 08-Sep-2020 | ||
GB-202011284-D0 | Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients | Inactive | 21-Jul-2020 |
Synairgen Signals
Synairgen Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Synairgen ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Biotechnology
Subindustry
Rank
Percentile

Synairgen FAQs
-
When was Synairgen founded?
Synairgen was founded in 2003.
-
Where is Synairgen headquartered?
Synairgen is headquartered in Southampton, United Kingdom.
-
What is the size of Synairgen?
Synairgen has 33 total employees.
-
What industry is Synairgen in?
Synairgen’s primary industry is Drug Discovery.
-
Is Synairgen a private or public company?
Synairgen is a Public company.
-
What is Synairgen’s stock symbol?
The ticker symbol for Synairgen is OMY.
-
What is the current market cap of Synairgen?
The current market capitalization of Synairgen is $8.42M.
-
Who are Synairgen’s competitors?
Verona Pharma, Ventus Therapeutics, Pulmatrix, Theravance Biopharma, and Savara are some of the 31 competitors of Synairgen.
-
What is Synairgen’s annual earnings per share (EPS)?
Synairgen’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »